IBRXImmunityBio, Inc.

Filed with the SEC on November 9, 2026 | Form 8-K (Items 2.02, 9.01) Current Price: $6.61 | Today's Change: -23.45%

---

What Happened

ImmunityBio, Inc. filed an 8-K with the SEC on November 9, 2026 disclosing its third-quarter FY2026 financial results. The company reported revenues of $75.0 million for the quarter, while recording a net loss of $289.5 million (-$0.32 per basic and diluted share). The operating loss for the period came in at $191.3 million, indicating that operating expenses alone substantially exceeded the company's revenue base, before accounting for items below the operating line that further widened the net loss.

---

Why It Matters

The magnitude of the gap between revenue and net loss is the defining feature of these results. While $75 million in quarterly revenue represents meaningful commercial activity — and is relevant context given StockWatch's existing initiating coverage on this name — the $289.5 million net loss dwarfs that top-line figure by a ratio of nearly 4-to-1. The operating loss of $191.3 million alone is roughly 2.5 times reported revenue, signaling that the company is still in a deeply cash-intensive phase of its development and commercial ramp. For investors, the near-term picture centers on the pace at which revenue can grow relative to the ongoing cash burn, and how the gap between the two may evolve over coming quarters. The market's immediate reaction — a single-session decline of more than 23% — indicates that the results fell well short of investor expectations.

---

Analysis

A few key dynamics are worth watching from these numbers:

• The disconnect between operating loss and net loss is significant. The operating loss was $191.3 million, but the net loss expanded to $289.5 million — a gap of roughly $98 million attributable to items below the operating line, such as interest expense, non-cash charges, or other non-operating items not separately broken out in the XBRL data provided. Investors should examine the full income statement in the accompanying exhibit for a complete picture of what drove this further widening.

• Revenue of $75 million is not trivial. The company does have a commercial revenue base, which distinguishes it from pure development-stage biotechs. However, with an operating cost structure that is producing a $191 million quarterly operating loss against that revenue, profitability remains a distant target absent either dramatic revenue acceleration or significant cost restructuring.

• The stock's sharp decline suggests expectations were not met. The more than 23% single-day drop in IBRX shares following this disclosure indicates that the market had priced in a materially better outcome. Whether that reflects revenue coming in below expectations, the loss being larger than anticipated, or guidance commentary in the earnings call, the filing itself does not specify — investors should consult the full earnings release and any accompanying management commentary filed as an exhibit.

• What to watch next: The trajectory of revenue growth in Q4 FY2026 and beyond will be the primary indicator of whether the company is making progress toward narrowing these losses. The composition of the non-operating losses adding roughly $98 million beyond the operating loss is also a key area for scrutiny.

---

Disclaimer

This report is a news and informational analysis based solely on data contained in ImmunityBio's SEC filing dated November 9, 2026, and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell securities, or an equity research recommendation. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on IBRX, published 2026-09-11. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-09. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-20261109.htm